Table 5.

Proportional hazards analyses at 1 year and 5 years in non-transplanted hepatocellular carcinoma patients with Barcelona Clinic Liver Cancer (BCLC) stage 0–A and B disease, by most efficacious treatment

HRs comparing most efficacious treatment with no treatment at 1 year and 5 years
Treatment modality	1-year HRc (95% CI)	P-valued	5-year HRc (95% CI)	P-valued
BCLC stage 0–A (n = 73a)
Chemotherapy or no treatment	Reference		Reference
Locoregional therapyb	0.24 (0.05–1.23)	0.9	0.11 (0.02–0.56)	0.002
Radiofrequency ablation	0.13 (0.02–0.78)	0.03	0.08 (0.02–0.40)	0.008
Resection	0.19 (0.04–0.88)	0.03	0.05 (0.01–0.26)	0.0003
BCLC stage B (n = 104a)
Chemotherapy or no treatment	Reference		Reference
Locoregional therapyb	0.57 (0.26–1.27)	0.17	0.82 (0.44–1.51)	0.52
Radiofrequency ablation	0.10 (0.02–0.47)	0.003	0.54 (0.27–1.10)	0.09
Resection	0.23 (0.06–0.85)	0.03	0.27 (0.12–0.60)	0.002

HRs at 1 year and 5 years comparing most efficacious treatment with LRT in non-transplanted patients with BCLC stage B diseasea
Treatment modality	1-year HRc (95% CI)	P-valued	5-year HRc (95% CI)	P-valued
Locoregional therapyb	Reference		Reference
Radiofrequency ablation	0.17 (0.04–0.74)	0.02	0.63 (0.34–1.11)	0.13
Resection	0.38 (0.11–1.33)	0.13	0.31 (0.14–0.66)	0.002

^aTransplant patients (10 BCLC stage 0–A and one BCLC stage B) were excluded from these analyses.

^bLRTs include microwave ablation, transarterial embolization, transarterial chemoembolization and percutaneous ethanol injection.

^cAge-adjusted HRs were calculated using Cox proportional hazards modelling in sas Version 9.2.

^dP-values were calculated using Fisher's exact test or chi-squared tests for categorical variables; continuous variables were rank-transformed.

HR, hazards ratio; 95% CI, 95% confidence interval; LRT, locoregional therapy.